#United States #New York #Securities Fraud #Rosen Law Firm #ADMA Biologics

ADMA Biologics Investors Can Join Class Action Lawsuit

ADMA Biologics, Inc. (NASDAQ: ADMA) faces allegations of securities fraud, prompting a class action lawsuit that may provide a path for investors to seek compensation. The lawsuit, initiated by the well-known Rosen Law Firm, claims that the company made false statements and failed to disclose significant transactions during the class period from August 9, 2024, to March 25, 2026.

As an investor in ADMA Biologics, it is crucial to be aware of the details surrounding this legal action. The deadline to apply as the lead plaintiff is approaching on August 10, 2026. Acting as a lead plaintiff means taking on the responsibility of representing the interests of all shareholders who purchased stocks during the disclosed class period.

Understanding the Claims

According to the lawsuit, the defendants allegedly committed several infractions:
1. Undisclosed Related Party Transactions: The company is accused of engaging in transactions that were not appropriately disclosed to investors, potentially misleading them regarding the company's financial integrity.
2. Channel Stuffing: This fraudulent practice may have been employed by the company to inflate revenue numbers. By shipping excessive amounts of product to customers without their actual demand, ADMA might have created a false representation of its sales performance.
3. Inadequate Internal Controls: Claims suggest that ADMA lacked sufficient internal controls to manage its financial reporting accurately, resulting in misleading financial statements.
4. Materially False Statements: The allegations highlight that the overall communications regarding ADMA's business operations and future prospects were misleading and lacked a reliable foundation at all relevant times.

These accusations can have serious implications for investors. When the actual facts of the case come to light, it can lead to financial losses for those who relied on the misleading information.

What Investors Can Do

If you purchased ADMA Biologics securities during the outlined class period, you may be eligible for monetary compensation, with no out-of-pocket expenses required, thanks to the contingency fee arrangement offered by the Rosen Law Firm. To get involved:

• - Visit Rosen Legal's official site.
• - Reach out toll-free to Phillip Kim, Esq. at 866-767-3653.
• - You can also email the firm at [email protected] for inquiries about your potential participation.

It is essential to understand that no class has yet been certified. Until such certification occurs, investors are not represented by legal counsel unless they actively retain an attorney. Investors have choices - they can select preferred legal counsel or opt to remain absent from collective participation.

The Importance of Legal Representation

As noted, the selection of a competent legal firm to represent investors is paramount. Not all legal representatives possess comparable experience or success rates in managing securities class actions. The Rosen Law Firm is particularly noteworthy, as it has a strong track record—having secured the largest-ever securities class action settlement against a Chinese company and a consistent ranking at the forefront of securities settlements annually since 2013.

For those considering joining the lawsuit, remember that the influence of the lead plaintiff can drive the direction of the case, making it vital to act swiftly and securely claim your position.

In conclusion, if you are an investor who purchased ADMA Biologics securities within the specified timeframe, you still have time to act. Engage with the legal insights provided by the Rosen Law Firm, consider your options, and make an informed decision about joining this pivotal class action aimed at reclaiming investment integrity and securing potential compensation.